27/11/2007,10535187II.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 08:20:53 ON 26 NOV 2007
FILE 'HCAPLUS' ENTERED AT 08:20:53 ON 26 NOV 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.84	519.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-24.96	-24.96

```
=> s l6/P and l3/ract
            87 L6/P
            39 L3
       3047744 RACT/RL
            32 L3/RACT
                 (L3 (L) RACT/RL)
L8          32 L6/P AND L3/RACT

=> d ed abs ibib hitstr tot
```

L8 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 03 Aug 2007
GI


I


II


III

AB A process for the preparation of N-[1-(S)-ethoxycarbonyl-1-butyl]-L-alanine-DMT complex (I) by reaction of N-[1-(S)-ethoxycarbonyl-1-butyl]-L-alanine with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride in a solvent and its use in the synthesis of perindopril, perindopril erbumine or pharmaceutically acceptable salts by reaction of I with compound (II) (R1 = aryl, alkyl, or silyl protective group) in a solvent, following by deprotection of compound (III) using suitable deprotecting agent, is described. Thus, N-[1-(S)-ethoxycarbonyl-1-butyl]-L-alanine and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride were mixed in THF and stirred for about 10 min at t° = 20-25° under nitrogen. To the resulting solution contained complex I was added (2S, 3aS, 7aS)-benzyl-perhydroindole-2-carboxylate at t° = 20-25° under nitrogen, and after separation and purification 1.5 g of perindopril benzyl ester was obtained, which was transformed into perindopril tert-Bu amine salt.

ACCESSION NUMBER: 2007:845244 HCAPLUS
DOCUMENT NUMBER: 147:212285
TITLE: Process for the preparation of N-[1-(S)-ethoxycarbonyl-1-butyl]-(s)-alanine-DMT complex and its use in the preparation of perindopril
INVENTOR(S): Joshi, Narendra Shriram; Pradhan, Nitin Sharad Chandra

L8 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Limited, India
SOURCE: PCT Int. Appl., 16pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007085933	A2	20070802	WO 2007-IB150	20070123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	IN 2006-MU125	A 20060125
	US 2006-792875P	P 20060418

OTHER SOURCE(S): CASREACT 147:212285; MARPAT 147:212285
IT 82834-16-0P, Perindopril 107133-36-8P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ethoxycarbonylbutyl alanine DMT complex and its use in preparation of perindopril and perindopril erbumine)
RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-

L8 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N

IT 122454-52-8P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ethoxycarbonylbutyl alanine DMT complex and its use in preparation of perindopril and perindopril erbumine)
RN 122454-52-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, phenylmethyl ester, (2S,3aS,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L8 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 23 Feb 2007
AB The present invention relates to a new process for the preparation of pure
perindopril erbumine. The present invention also relates to a new process
for the preparation of crystalline form D of perindopril erbumine. Crystalline
perindopril erbumine is formulated into a pharmaceutically acceptable
dosage form. Thus, (2S,3aS,7aS)-2-carboxyperhydroindole benzyl ester was
treated with N-((S)-1-carbetoxybutyl)-(S)-alanine in acetonitrile in
presence of O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate to afford 88% perindopril benzyl ester.
Hydrogenolysis of crude perindopril benzyl ester over 10% Pd/C gave crude
perindopril (2.33% of diketopiperazine I, 0.54% of diketopiperazine II).
Crude perindopril was dissolved in wet Et acetate, insol. impurities were
filtered off, tert-butylamine was added to the filtrate, the mixture was
heated to boiling, filtered and then cooled to 0° to precipitate
perindopril erbumine in crystalline form D.
ACCESSION NUMBER: 2007:200622 HCAPLUS
DOCUMENT NUMBER: 146:259148
TITLE: A process for the preparation of perindopril erbumine for dosage forms
INVENTOR(S): Ham, Zoran; Furlan, Borut
PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia
SOURCE: PCT Int. Appl., 26pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007020012	A1	20070222	WO 2006-EP7926	20060810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: SI 2005-232 A 20050812

IT 107133-36-8P, Perindopril erbumine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of perindopril erbumine and its crystalline form for dosage forms)
RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-

L8 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 122454-52-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, phenylmethyl ester, (2S,3aS,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L8 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.
with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N

IT 82834-16-0P, Perindopril 122454-52-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of perindopril erbumine and its crystalline form for dosage forms)
RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L8 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 16 Feb 2007
AB The present invention relates to a novel crystalline η form of perindopril
erbumine exhibiting characteristic 2θ values and having purity not less than 99.8%. More particularly, the present invention relates to a process for the preparation of the novel crystalline η form of perindopril
erbumine comprising the steps of (i) dissolving perindopril erbumine monohydrate in halogenated hydrocarbon solvent; (ii) adding a co-solvent to the mixture of the content obtained from step (i); (iii) removing the mixture of solvents under reduced pressure in the range of 25 to 35°; and (iv) filtering off the solid obtained.
ACCESSION NUMBER: 2007:175534 HCAPLUS
DOCUMENT NUMBER: 146:236294
TITLE: Preparation of novel crystalline η (eta) form of perindopril erbumine
INVENTOR(S): Ujagare, Ashish; Kochrekar, D. A.; Sarjekar, Pushpalata
PATENT ASSIGNEE(S): Arch Pharmalabs Limited, India
SOURCE: PCT Int. Appl., 21pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007017894	A2	20070215	WO 2006-IN156	20060504
WO 2007017894	A3	20070510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: IN 2005-MU561 A 20050505

IT 107133-36-8P, Perindopril erbumine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PUR
(Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation and purification of η crystal form of perindopril erbumine of
high purity and good solubility)
RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.
with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)

L8 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N

IT 690267-97-1P, Perindopril erbumine monohydrate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN
(Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation and purification of η crystal form of perindopril erbumine of
high purity and good solubility)
RN 690267-97-1 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.
with 2-methyl-2-propanamine, hydrate (1:1:1) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).

L8 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 924637-23-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and purification of η crystal form of perindopril erbumine of
high purity and good solubility)
RN 924637-23-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, phenylmethyl ester, hydrochloride (1:1), (2S,3aS,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L8 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 75-64-9
CMF C4 H11 N

IT 122454-52-8P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and purification of η crystal form of perindopril erbumine of
high purity and good solubility)
RN 122454-52-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, phenylmethyl ester, (2S,3aS,7aS)- (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 4 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 16 Feb 2007
AB The present invention relates to a novel crystalline form of perindopril erbumine monohydrate exhibiting characteristic 2θ values and having purity not less than 99.8%. More particularly, the present invention relates to a process for the preparation of the novel crystalline form of perindopril erbumine monohydrate comprising steps of (i) dissolving perindopril erbumine in water; (ii) extracting the solution with toluene or
xylene; (iii) removing water from the aqueous layer obtained from step (i),
adding a polar solvent to the mass obtained from step (ii) at 20 to 45°, and (iv) filtering off the solid obtained.

ACCESSION NUMBER: 2007:175533 HCAPLUS
DOCUMENT NUMBER: 146:236293
TITLE: Preparation of novel crystalline form of perindopril erbumine monohydrate
INVENTOR(S): Ujagare, Ashish; Kochrekar, D. A.; Sarjekar, Pushpalata
PATENT ASSIGNEE(S): Arch Pharmalabs Limited, India
SOURCE: PCT Int. Appl., 21pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007017893	A2	20070215	WO 2006-IN155	20060504
WO 2007017893	A3	20070510		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: IN 2005-MU562 A 20050505

IT 690267-97-1P, Perindopril erbumine monohydrate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PUR
(Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation and purification of crystalline form of perindopril erbumine monohydrate
of high purity)
RN 690267-97-1 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd.
with 2-methyl-2-propanamine, hydrate (1:1:1) (CA INDEX NAME)